Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab + Cetuximab in Advanced CRC or SCCHN
NCT02110082Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of urelumab in colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence, potential significance, and clinical importance of adverse events at 2 years. Started Apr 2014; status: completed.
02
Drugs
urelumab
03
Conditions
colorectal cancer (CRC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02110082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110082.